Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Matteo Santoni(University of Macerata), Nicola Battelli(Ospedale di Macerata), Jeffrey Graham(University of Calgary), Sebastiano Buti(University of Parma), Fabio Calabrò(Carlo Forlanini Hospital), Cinzia Ortega(Candiolo Cancer Institute), Camillo Porta(University of Pavia), Michèle Milella(National Cancer Institute), Orazio Caffo(Ospedale Santa Chiara), Nuno Vau(Champalimaud Foundation), Luca Galli(University of Pisa), Giacomo Cartenì(Ospedale Antonio Cardarelli), Francesco Carrozza(Ospedale per gli Infermi), Giulia Sorgentoni(Ospedale di Macerata), Mimma Rizzo(University of Pavia), Maria Giuseppa Vitale(University of Modena and Reggio Emilia), Alessandro Conti(Krankenhaus Brixen), Marc Matrana(Ochsner Medical Center), Franco Morelli(Casa Sollievo della Sofferenza), Elena Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Piva, Rodolfo Montironi(Marche Polytechnic University), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorena Incorvaia(University of Palermo), Alessandra Mosca(Candiolo Cancer Institute), Sergio Bracarda(Azienda Ospedaliera S.Maria), Riccardo Ricotta(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Paolo Andrea Zucali(Humanitas University), Alessia Cimadamore(University of Udine), Francesco Massari(Altera (United States)), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Francesco Atzori(Azienda Ospedaliero-Universitaria Cagliari), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Sarah Scagliarini(Ospedale Antonio Cardarelli), Cristina Masini(Ospedale Santa Maria), Simon J. Crabb(University of Southampton), Giuseppe Fornarini(Ospedale Policlinico San Martino), Umberto Basso(Istituto Oncologico Veneto), Pierangela Sepe(Fondazione IRCCS Istituto Nazionale dei Tumori), Alain Gelibter(Policlinico Umberto I), Marina Scarpelli(Marche Polytechnic University), Daniele Santini(Policlinico Umberto I), Liang Cheng(Brown University), Antonio López-Beltrán(University of Córdoba), Erin Pierce(Ochsner Medical Center), Vittorio Paolucci(Sana Klinikum Offenbach), Angelo Martignetti, Daniel Y.C. Heng(University of Calgary), Sara Merler(Azienda Ospedaliera Universitaria Integrata Verona)
Cited by 31
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821